Trending
Paul Connelly's Avatar

Paul Connelly

@pconnelly

Consultant Endocrinologist - Glasgow Interested in sex steroids, pituitary disease and mineral metabolism.

84
Followers
149
Following
14
Posts
16.09.2024
Joined
Posts Following

Latest posts by Paul Connelly @pconnelly

Hypoparanoid - anxiety relating to calcium results

03.03.2025 21:37 ๐Ÿ‘ 0 ๐Ÿ” 0 ๐Ÿ’ฌ 0 ๐Ÿ“Œ 0

Nothing more endocrine than pondering over something so long that it doesn't matter any more! Well done!

03.12.2024 18:40 ๐Ÿ‘ 0 ๐Ÿ” 0 ๐Ÿ’ฌ 0 ๐Ÿ“Œ 0

I take it you are taking more time over your D&E application???

03.12.2024 18:32 ๐Ÿ‘ 0 ๐Ÿ” 0 ๐Ÿ’ฌ 1 ๐Ÿ“Œ 0
Post image

Attended the brilliant Reproductive Endocrinology meeting in London. Superb speakers and topics. Excited to put this new knowledge into practice! #endosky #medsky

03.12.2024 17:56 ๐Ÿ‘ 1 ๐Ÿ” 0 ๐Ÿ’ฌ 0 ๐Ÿ“Œ 0

The advances in hypopara management keep coming!

01.12.2024 09:54 ๐Ÿ‘ 0 ๐Ÿ” 0 ๐Ÿ’ฌ 0 ๐Ÿ“Œ 0

I really wish I could! That would be some paper. I haven't seen any convincing data either way. I worry a RCT would be impossible.

22.11.2024 19:01 ๐Ÿ‘ 1 ๐Ÿ” 0 ๐Ÿ’ฌ 1 ๐Ÿ“Œ 0

Can you provide a plot with mortality directly attributable to hyponatraemia?

22.11.2024 16:15 ๐Ÿ‘ 1 ๐Ÿ” 0 ๐Ÿ’ฌ 1 ๐Ÿ“Œ 0

It's my first Christmas as a consultant.

What do I get my amazing secretary?

#medsky

22.11.2024 08:45 ๐Ÿ‘ 1 ๐Ÿ” 0 ๐Ÿ’ฌ 0 ๐Ÿ“Œ 0

The slow-correcting heart failure patient will have higher mortality and a longer inpatient stay compared to the rapid-correcting patient with alcohol dependence and suppressed AVP. Their risks of ODS are not equivalent.

19.11.2024 16:52 ๐Ÿ‘ 3 ๐Ÿ” 0 ๐Ÿ’ฌ 2 ๐Ÿ“Œ 0

The omission of hypertonic saline strategies or hyponatraemia aetiologies limits it's utility. Not planning on changing my practice based on this paper having seen ODS first hand in rapid correctors.

19.11.2024 16:48 ๐Ÿ‘ 1 ๐Ÿ” 0 ๐Ÿ’ฌ 1 ๐Ÿ“Œ 0

You do wonder about how the pancreas copes with hypercalcaemia in PHP

18.11.2024 21:01 ๐Ÿ‘ 2 ๐Ÿ” 0 ๐Ÿ’ฌ 0 ๐Ÿ“Œ 0
Preview
Higher risk of incident diabetes among patients with primary hyperparathyroidism Objectives There is relatively scarce data regarding the association between primary hyperparathyroidism (PHPT) and incident diabetes in large population-based longitudinal studies. We aimed to eval.....
18.11.2024 20:55 ๐Ÿ‘ 1 ๐Ÿ” 0 ๐Ÿ’ฌ 0 ๐Ÿ“Œ 1
Preview
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity | NEJM Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor...

Another GLP-1 drug success. Tirzepatide in heart failure with preserved ejection fraction (HFpEF) with longer term follow-up than 2 previous trials with semaglutide
nejm.org/doi/full/10....
in people with BMI >30; no data yet for HFpEF in people without obesity

16.11.2024 15:12 ๐Ÿ‘ 242 ๐Ÿ” 38 ๐Ÿ’ฌ 3 ๐Ÿ“Œ 1

Only a single dose was administered - could a further dose at 6 months and/or BTM monitoring have mitigated the BMD loss?

16.11.2024 13:47 ๐Ÿ‘ 0 ๐Ÿ” 0 ๐Ÿ’ฌ 0 ๐Ÿ“Œ 0
Preview
Zoledronate Sequential Therapy to Prevent Bone Loss After Stopping Denosumab This randomized clinical trial examines the use of sequential therapy with zoledronate to prevent loss of bone mineral density after denosumab discontinuation in the first year.

Sequential zoledronic acid following densoumab did not prevent loss of lumbar spine BMD @jamacurrent.bsky.social

16.11.2024 13:44 ๐Ÿ‘ 0 ๐Ÿ” 0 ๐Ÿ’ฌ 1 ๐Ÿ“Œ 0